{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T16:56:13Z","timestamp":1790787373086,"version":"4.1.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,8,13]],"date-time":"2020-08-13T00:00:00Z","timestamp":1597276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,8,13]],"date-time":"2020-08-13T00:00:00Z","timestamp":1597276800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Surg Onc"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Recent phase III randomized trials have suggested that neoadjuvant chemotherapy followed by interval debulking surgery (NACT-IDS) is a treatment option for patients with advanced epithelial ovarian cancer. This study aimed to use CA-125 and computed tomography (CT) scanning to generate a simple and clinically applicable model of predicting complete cytoreduction by interval debulking surgery (IDS) and the overall survival in patients who receive taxane\/platinum-based chemotherapy as neoadjuvant chemotherapy (NACT).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Patients with stage IIIc or IV epithelial ovarian cancer who underwent taxane\/platinum-based NACT followed by IDS in Gunma Prefectural Cancer Center, Takasaki General Medical Center, and Gunma University from April 2009 to March 2015 were included. Patients underwent a CT scan to confirm confirm tumors unresectable by standard surgery before NACT. CA-125 levels were measured pre-NACT, after each cycle of NACT, and before IDS. CT was also performed before IDS to evaluate tumor metastasis. Data were collected retrospectively and analyzed to determine the predictive factors of complete resection and overall survival.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Among 63 patients who received NACT-IDS, 43 and 20 patients had stages IIIc and IV epithelial ovarian cancer at diagnosis, respectively. CT predictors of residual tumors after IDS such as extra-ovarian implants (<jats:italic>P<\/jats:italic>= 0.009) and omental cakes (<jats:italic>P<\/jats:italic>= 0.038) were not present. Univariate analysis revealed that the independent factors for overall survival were no residual tumor by IDS (<jats:italic>P<\/jats:italic>= 0.0016) and CA125 \u2264 20\u2009U\/ml before IDS (<jats:italic>P<\/jats:italic>= 0.0011).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Although this study had a small sample size, NACT-IDS used to completely remove macroscopic disease which significantly improved the prognosis of patients with preoperative CA-125 \u2264 20\u2009U\/ml. Results from this study provide useful information for future studies on the management of patients with advanced epithelial ovarian cancer.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s12957-020-01978-6","type":"journal-article","created":{"date-parts":[[2020,8,13]],"date-time":"2020-08-13T15:50:09Z","timestamp":1597333809000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Nadir CA-125 serum levels during neoadjuvant chemotherapy and no residual tumor at interval debulking surgery predict prognosis in advanced stage ovarian cancer"],"prefix":"10.1186","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5738-3418","authenticated-orcid":false,"given":"Kazuto","family":"Nakamura","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshikazu","family":"Kitahara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshio","family":"Nishimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soichi","family":"Yamashita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiko","family":"Kigure","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ikuro","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuya","family":"Kanuma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,8,13]]},"reference":[{"key":"1978_CR1","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1056\/NEJMoa0908806","volume":"363","author":"I Vergote","year":"2010","unstructured":"Vergote I, Trope CG, Amant F, Kristensen GB, Ehlen T, Johnson N, et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med. 2010;363:943\u201353.","journal-title":"N Engl J Med"},{"key":"1978_CR2","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/S0140-6736(14)62223-6","volume":"386","author":"S Kehoe","year":"2015","unstructured":"Kehoe S, Hook J, Nankivell M, Jayson GC, Kitchener H, Lopes T, et al. Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial. Lancet. 2015;386:249\u201357.","journal-title":"Lancet"},{"key":"1978_CR3","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/j.ygyno.2011.08.030","volume":"123","author":"MM Thrall","year":"2011","unstructured":"Thrall MM, Gray HJ, Symons RG, Weiss NS, Flum DR, Goff BA. Neoadjuvant chemotherapy in the Medicare cohort with advanced ovarian cancer. Gynecol Oncol. 2011;123:461\u20136.","journal-title":"Gynecol Oncol"},{"key":"1978_CR4","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1245\/s10434-011-2100-x","volume":"19","author":"JA Rauh-Hain","year":"2012","unstructured":"Rauh-Hain JA, Rodriguez N, Growdon WB, Goodman AK, Boruta DM 2nd, Horowitz NS, et al. Primary debulking surgery versus neoadjuvant chemotherapy in stage IV ovarian cancer. Ann Surg Oncol. 2012;19:959\u201365.","journal-title":"Ann Surg Oncol"},{"key":"1978_CR5","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1002\/jso.23171","volume":"107","author":"MA Glasgow","year":"2013","unstructured":"Glasgow MA, Yu H, Rutherford TJ, Azodi M, Silasi DA, Santin AD, et al. Neoadjuvant chemotherapy (NACT) is an effective way of managing elderly women with advanced stage ovarian cancer (FIGO stage IIIC and IV). J Surg Oncol. 2013;107:195\u2013200.","journal-title":"J Surg Oncol"},{"key":"1978_CR6","doi-asserted-by":"publisher","first-page":"3854","DOI":"10.1200\/JCO.2016.68.1239","volume":"34","author":"LA Meyer","year":"2016","unstructured":"Meyer LA, Cronin AM, Sun CC, Bixel K, Bookman MA, Cristea MC, et al. Use and effectiveness of neoadjuvant chemotherapy for treatment of ovarian cancer. J Clin Oncol. 2016;34:3854\u201363.","journal-title":"J Clin Oncol"},{"key":"1978_CR7","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.ygyno.2016.11.021","volume":"144","author":"SE Gill","year":"2017","unstructured":"Gill SE, McGree ME, Weaver AL, Cliby WA, Langstraat CL. Optimizing the treatment of ovarian cancer: neoadjuvant chemotherapy and interval debulking versus primary debulking surgery for epithelial ovarian cancers likely to have suboptimal resection. Gynecol Oncol. 2017;144:266\u201373.","journal-title":"Gynecol Oncol"},{"key":"1978_CR8","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1002\/cncr.20376","volume":"101","author":"SC Dowdy","year":"2004","unstructured":"Dowdy SC, Mullany SA, Brandt KR, Huppert BJ, Cliby WA. The utility of computed tomography scans in predicting suboptimal cytoreductive surgery in women with advanced ovarian carcinoma. Cancer. 2004;101:346\u201352.","journal-title":"Cancer"},{"key":"1978_CR9","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1200\/JCO.2006.07.7800","volume":"25","author":"AE Axtell","year":"2007","unstructured":"Axtell AE, Lee MH, Bristow RE, Dowdy SC, Cliby WA, Raman S, et al. Multi-institutional reciprocal validation study of computed tomography predictors of suboptimal primary cytoreduction in patients with advanced ovarian cancer. J Clin Oncol. 2007;25:384\u20139.","journal-title":"J Clin Oncol"},{"key":"1978_CR10","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1097\/IGC.0b013e31822925c0","volume":"21","author":"U Metser","year":"2011","unstructured":"Metser U, Jones C, Jacks LM, Bernardini MQ, Ferguson S. Identification and quantification of peritoneal metastases in patients with ovarian cancer with multidetector computed tomography: correlation with surgery and surgical outcome. Int J Gynecol Cancer. 2011;21:1391\u20138.","journal-title":"Int J Gynecol Cancer"},{"key":"1978_CR11","doi-asserted-by":"publisher","first-page":"462 e461","DOI":"10.1016\/j.ajog.2013.07.016","volume":"209","author":"A Fagotti","year":"2013","unstructured":"Fagotti A, Vizzielli G, De Iaco P, Surico D, Buda A, Mandato VD, et al. Am J Obstet Gynecol. 2013;209:462 e461\u201311.","journal-title":"Am J Obstet Gynecol"},{"key":"1978_CR12","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.ygyno.2009.09.015","volume":"116","author":"A Fagotti","year":"2010","unstructured":"Fagotti A, Fanfani F, Vizzielli G, Gallotta V, Ercoli A, Paglia A, et al. Should laparoscopy be included in the work-up of advanced ovarian cancer patients attempting interval debulking surgery? Gynecol Oncol. 2010;116:72\u20137.","journal-title":"Gynecol Oncol"},{"key":"1978_CR13","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.ygyno.2008.10.010","volume":"112","author":"DS Chi","year":"2009","unstructured":"Chi DS, Zivanovic O, Palayekar MJ, Eisenhauer EL, Abu-Rustum NR, Sonoda Y, et al. A contemporary analysis of the ability of preoperative serum CA-125 to predict primary cytoreductive outcome in patients with advanced ovarian, tubal and peritoneal carcinoma. Gynecol Oncol. 2009;112:6\u201310.","journal-title":"Gynecol Oncol"},{"key":"1978_CR14","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/j.ygyno.2012.02.006","volume":"125","author":"N Rodriguez","year":"2012","unstructured":"Rodriguez N, Rauh-Hain JA, Shoni M, Berkowitz RS, Muto MG, Feltmate C, et al. Changes in serum CA-125 can predict optimal cytoreduction to no gross residual disease in patients with advanced stage ovarian cancer treated with neoadjuvant chemotherapy. Gynecol Oncol. 2012;125:362\u20136.","journal-title":"Gynecol Oncol"},{"key":"1978_CR15","doi-asserted-by":"publisher","first-page":"3194","DOI":"10.1200\/JCO.2003.02.153","volume":"21","author":"RF Ozols","year":"2003","unstructured":"Ozols RF, Bundy BN, Greer BE, Fowler JM, Clarke-Pearson D, Burger RA, et al. Gynecologic oncology G: phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a gynecologic oncology group study. J Clin Oncol. 2003;21:3194\u2013200.","journal-title":"J Clin Oncol"},{"key":"1978_CR16","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1200\/JCO.2008.19.1684","volume":"27","author":"MA Bookman","year":"2009","unstructured":"Bookman MA, Brady MF, McGuire WP, Harper PG, Alberts DS, Friedlander M, et al. Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a phase III trial of the gynecologic cancer intergroup. J Clin Oncol. 2009;27:1419\u201325.","journal-title":"J Clin Oncol"},{"key":"1978_CR17","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/j.ygyno.2013.05.040","volume":"130","author":"SJ Chang","year":"2013","unstructured":"Chang SJ, Hodeib M, Chang J, Bristow RE. Survival impact of complete cytoreduction to no gross residual disease for advanced-stage ovarian cancer: a meta-analysis. Gynecol Oncol. 2013;130:493\u20138.","journal-title":"Gynecol Oncol"},{"key":"1978_CR18","doi-asserted-by":"crossref","unstructured":"Morrison J, Haldar K, Kehoe S, Lawrie TA. Chemotherapy versus surgery for initial treatment in advanced ovarian epithelial cancer. Cochrane Database Syst Rev. 2012:CD005343.","DOI":"10.1002\/14651858.CD005343.pub3"},{"key":"1978_CR19","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.ygyno.2016.05.022","volume":"143","author":"AA Wright","year":"2016","unstructured":"Wright AA, Bohlke K, Armstrong DK, Bookman MA, Cliby WA, Coleman RL, et al. Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: Society of Gynecologic Oncology and American Society of clinical oncology clinical practice guideline. Gynecol Oncol. 2016;143:3\u201315.","journal-title":"Gynecol Oncol"},{"key":"1978_CR20","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.ygyno.2014.09.002","volume":"135","author":"PE Colombo","year":"2014","unstructured":"Colombo PE, Labaki M, Fabbro M, Bertrand M, Mourregot A, Gutowski M, et al. Impact of neoadjuvant chemotherapy cycles prior to interval surgery in patients with advanced epithelial ovarian cancer. Gynecol Oncol. 2014;135:223\u201330.","journal-title":"Gynecol Oncol"},{"key":"1978_CR21","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.ygyno.2017.08.006","volume":"147","author":"AD Altman","year":"2017","unstructured":"Altman AD, McGee J, May T, Lane K, Lu L, Xu W, et al. Neoadjuvant chemotherapy and chemotherapy cycle number: a national multicentre study. Gynecol Oncol. 2017;147:257\u201361.","journal-title":"Gynecol Oncol"},{"key":"1978_CR22","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/j.ejogrb.2011.07.014","volume":"159","author":"E Stoeckle","year":"2011","unstructured":"Stoeckle E, Boubli B, Floquet A, Brouste V, Sire M, Croce S, et al. Optimal timing of interval debulking surgery in advanced ovarian cancer: yet to be defined? Eur J Obstet Gynecol Reprod Biol. 2011;159:407\u201312.","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"1978_CR23","doi-asserted-by":"crossref","unstructured":"da Costa MV, de Souza Fede AB, Dos Anjos CH, da Silva JR, Sanchez FB, da Silva Bessa LR, Del Pilar Estevez Diz M et al.: Neoadjuvant chemotherapy with six cycles of carboplatin and paclitaxel in advanced ovarian cancer patients unsuitable for primary surgery: safety and effectiveness. Gynecol Oncol. 2014;132:287\u2013291.","DOI":"10.1016\/j.ygyno.2013.12.002"},{"key":"1978_CR24","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0183754","volume":"12","author":"YS Chung","year":"2017","unstructured":"Chung YS, Kim YJ, Lee I, Lee JY, Nam EJ, Kim S, et al. Impact of neoadjuvant chemotherapy and postoperative adjuvant chemotherapy cycles on survival of patients with advanced-stage ovarian cancer. PLoS One. 2017;12:e0183754.","journal-title":"PLoS One"},{"key":"1978_CR25","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1016\/j.ejso.2018.01.097","volume":"44","author":"A Phillips","year":"2018","unstructured":"Phillips A, Sundar S, Singh K, Nevin J, Elattar A, Kehoe S, et al. Complete cytoreduction after five or more cycles of neo-adjuvant chemotherapy confers a survival benefit in advanced ovarian cancer. Eur J Surg Oncol. 2018;44:760\u20135.","journal-title":"Eur J Surg Oncol"},{"key":"1978_CR26","doi-asserted-by":"publisher","first-page":"553","DOI":"10.3109\/07357908509039817","volume":"3","author":"JH Goldie","year":"1985","unstructured":"Goldie JH, Coldman AJ. A model for tumor response to chemotherapy: an integration of the stem cell and somatic mutation hypotheses. Cancer Investig. 1985;3:553\u201364.","journal-title":"Cancer Investig"},{"key":"1978_CR27","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1002\/1097-0142(20001001)89:7<1532::AID-CNCR17>3.0.CO;2-A","volume":"89","author":"RE Bristow","year":"2000","unstructured":"Bristow RE, Duska LR, Lambrou NC, Fishman EK, O'Neill MJ, Trimble EL, et al. A model for predicting surgical outcome in patients with advanced ovarian carcinoma using computed tomography. Cancer. 2000;89:1532\u201340.","journal-title":"Cancer"},{"key":"1978_CR28","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1016\/j.ygyno.2014.07.002","volume":"134","author":"RS Suidan","year":"2014","unstructured":"Suidan RS, Ramirez PT, Sarasohn DM, Teitcher JB, Mironov S, Iyer RB, et al. A multicenter prospective trial evaluating the ability of preoperative computed tomography scan and serum CA-125 to predict suboptimal cytoreduction at primary debulking surgery for advanced ovarian, fallopian tube, and peritoneal cancer. Gynecol Oncol. 2014;134:455\u201361.","journal-title":"Gynecol Oncol"},{"key":"1978_CR29","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s13048-018-0415-y","volume":"11","author":"E Ghisoni","year":"2018","unstructured":"Ghisoni E, Katsaros D, Maggiorotto F, Aglietta M, Vaira M, De Simone M, et al. A predictive score for optimal cytoreduction at interval debulking surgery in epithelial ovarian cancer: a two- centers experience. J Ovarian Res. 2018;11:42.","journal-title":"J Ovarian Res"},{"key":"1978_CR30","doi-asserted-by":"publisher","first-page":"2457","DOI":"10.1200\/JCO.2014.60.5212","volume":"33","author":"S Bohm","year":"2015","unstructured":"Bohm S, Faruqi A, Said I, Lockley M, Brockbank E, Jeyarajah A, et al. Chemotherapy response score: development and validation of a system to quantify histopathologic response to neoadjuvant chemotherapy in tubo-ovarian high-grade serous carcinoma. J Clin Oncol. 2015;33:2457\u201363.","journal-title":"J Clin Oncol"},{"key":"1978_CR31","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1016\/j.ygyno.2018.12.012","volume":"152","author":"A Bregar","year":"2019","unstructured":"Bregar A, Mojtahed A, Kilcoyne A, Kurra V, Melamed A, Growdon W, et al. CT prediction of surgical outcome in patients with advanced epithelial ovarian carcinoma undergoing neoadjuvant chemotherapy. Gynecol Oncol. 2019;152:568\u201373.","journal-title":"Gynecol Oncol"},{"key":"1978_CR32","doi-asserted-by":"crossref","unstructured":"McNulty M, Das A, Cohen PA, Dean A. Measuring response to neoadjuvant chemotherapy in high-grade serous tubo-ovarian carcinoma: an analysis of the correlation between CT imaging and chemotherapy response score. Int J Gynecol Cancer. 2019.","DOI":"10.1136\/ijgc-2019-000222"},{"key":"1978_CR33","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1007\/s00404-015-3813-z","volume":"293","author":"C Bian","year":"2016","unstructured":"Bian C, Yao K, Li L, Yi T, Zhao X. Primary debulking surgery vs. neoadjuvant chemotherapy followed by interval debulking surgery for patients with advanced ovarian cancer. Arch Gynecol Obstet. 2016;293:163\u20138.","journal-title":"Arch Gynecol Obstet"},{"key":"1978_CR34","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.ejogrb.2017.10.019","volume":"219","author":"CKM Vermeulen","year":"2017","unstructured":"Vermeulen CKM, Tadesse W, Timmermans M, Kruitwagen R, Walsh T. Only complete tumour resection after neoadjuvant chemotherapy offers benefit over suboptimal debulking in advanced ovarian cancer. Eur J Obstet Gynecol Reprod Biol. 2017;219:100\u20135.","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"1978_CR35","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1016\/j.ygyno.2014.09.005","volume":"135","author":"A Pelissier","year":"2014","unstructured":"Pelissier A, Bonneau C, Chereau E, de La Motte RT, Fourchotte V, Darai E, et al. CA125 kinetic parameters predict optimal cytoreduction in patients with advanced epithelial ovarian cancer treated with neoadjuvant chemotherapy. Gynecol Oncol. 2014;135:542\u20136.","journal-title":"Gynecol Oncol"},{"key":"1978_CR36","doi-asserted-by":"publisher","first-page":"1534","DOI":"10.1093\/jnci\/92.18.1534","volume":"92","author":"I Vergote","year":"2000","unstructured":"Vergote I, Rustin GJ, Eisenhauer EA, Kristensen GB, Pujade-Lauraine E, Parmar MK, et al. Re: new guidelines to evaluate the response to treatment in solid tumors [ovarian cancer]. Gynecologic cancer intergroup. J Natl Cancer Inst. 2000;92:1534\u20135.","journal-title":"J Natl Cancer Inst"},{"key":"1978_CR37","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/S1068-607X(98)00046-8","volume":"5","author":"HN Nguyen","year":"1998","unstructured":"Nguyen HN, Jacobson A, Patino-Paul R. New reference levels for CA125 in pre- and postmenopausal women. Prim Care Update Ob Gyns. 1998;5:157.","journal-title":"Prim Care Update Ob Gyns"},{"key":"1978_CR38","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1006\/gyno.1998.5018","volume":"69","author":"T Kurihara","year":"1998","unstructured":"Kurihara T, Mizunuma H, Obara M, Andoh K, Ibuki Y, Nishimura T. Determination of a normal level of serum CA125 in postmenopausal women as a tool for preoperative evaluation and postoperative surveillance of endometrial carcinoma. Gynecol Oncol. 1998;69:192\u20136.","journal-title":"Gynecol Oncol"},{"key":"1978_CR39","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.1200\/JCO.2005.04.7373","volume":"24","author":"M Markman","year":"2006","unstructured":"Markman M, Liu PY, Rothenberg ML, Monk BJ, Brady M, Alberts DS. Pretreatment CA-125 and risk of relapse in advanced ovarian cancer. J Clin Oncol. 2006;24:1454\u20138.","journal-title":"J Clin Oncol"}],"container-title":["World Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-020-01978-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12957-020-01978-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-020-01978-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,6]],"date-time":"2022-11-06T21:18:15Z","timestamp":1667769495000},"score":1,"resource":{"primary":{"URL":"https:\/\/wjso.biomedcentral.com\/articles\/10.1186\/s12957-020-01978-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,13]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1978"],"URL":"https:\/\/doi.org\/10.1186\/s12957-020-01978-6","relation":{},"ISSN":["1477-7819"],"issn-type":[{"value":"1477-7819","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,13]]},"assertion":[{"value":"23 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 July 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 August 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by the institutional review board (Gunma Prefectural Cancer Center) with approval reference 405-30081.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"200"}}